A
Angel Pharmaceuticals
Clinical-stage cancer and autoimmune disease drug development.
About Angel Pharmaceuticals
Angel Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2020, focused on developing and commercializing a pipeline of targeted investigational medicines for cancer, autoimmune, and infectious diseases, primarily within Greater China. The company was co-founded by U.S.-based Corvus Pharmaceuticals (NASDAQ: CRVS) and a consortium of Chinese investors, including Puissance Capital, Hisun Pharmaceuticals, and Tigermed. This strategic collaboration enables the clinical development and commercialization of Corvus's drug pipeline in China. Angel Pharmaceuticals is headquartered in Jiaxing, China, with research and development facilities in both Jiaxing and Burlingame, California. The business model centers on in-licensing and advancing clinical-stage candidates. Angel licensed the rights from Corvus to develop and commercialize three assets in greater China: soquelitinib (an ITK inhibitor), ciforadenant (an adenosine A2A receptor antagonist), and mupadolimab (a monoclonal antibody targeting CD73). The company also obtained global rights to Corvus's preclinical BTK inhibitor programs. Corvus is the largest shareholder, holding a significant equity stake. One of Corvus's co-founders, Dr. Richard A. Miller, who previously co-founded IDEC (leading to the development of rituximab) and Pharmacyclics (known for ibrutinib), serves on Angel Pharmaceuticals' board. The company's lead asset, soquelitinib, is an oral small molecule designed to selectively inhibit ITK (interleukin-2-inducible T-cell kinase), an enzyme crucial for T-cell function. Angel is advancing soquelitinib in multiple trials in China, including a Phase 1b/2 trial for atopic dermatitis and a planned Phase 2 trial for asthma, with initial data from the dermatitis trial expected in late 2026. Other pipeline candidates include ciforadenant, being studied for renal cell carcinoma, and mupadolimab for solid tumors like non-small cell lung cancer. The company aims to make these innovative drugs more accessible to patients in the region.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $14M | $55M | Corvus Pharmaceuticals · TG Sino-Dragon Fund | ↗ |
| SERIES AOther financing | Oct 2020 | $41M | $164M | Undisclosed | — |
Growth signals
Latest recorded traffic for Angel Pharmaceuticals is 950 monthly website visits.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Angel Pharmaceuticals in the Jiaxing ecosystem
The Angel Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Corvus Pharmaceuticals- TFTG Sino-Dragon Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Angel Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Angel Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








